NCT07003204

Brief Summary

Exudative pleural effusion (EPE) presents a diagnostic challenge, requiring accurate biomarkers to predict outcomes and guide treatment. The neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) in pleural fluid are emerging as potential prognostic markers. We aimed to assess the diagnostic and prognostic utility of pleural fluid NLR and MLR in EPE.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 11, 2025

Completed
14 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 25, 2025

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

May 26, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 26, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

June 4, 2025

Completed
Last Updated

June 4, 2025

Status Verified

May 1, 2025

Enrollment Period

14 days

First QC Date

May 26, 2025

Last Update Submit

May 26, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • MLR and NLR measuring in pleural fluid

    counting pleural fluid monocytes,lymphocytes and neutrophils

    1 month

Other Outcomes (1)

  • MLR and NLR measuring in pleural fluid

    one month

Study Arms (1)

only one group of patients

prospective cohort randomized control study

Procedure: medical thoracoscopy

Interventions

pleural fluid aspiration and cellular analysis

only one group of patients

Eligibility Criteria

Age18 Months+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

60 person with pleural effusion

You may qualify if:

  • adult patients aged 18-80 years with an EPE diagnosis confirmed by thoracentesis.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chest Department -Faculty of Medicine

Alexandria, Egypt, 11511, Egypt

Location

Related Links

Study Officials

  • mohamed Sabry eltarhony, lecturer

    Alexandria University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of chest diseases

Study Record Dates

First Submitted

May 26, 2025

First Posted

June 4, 2025

Study Start

May 11, 2025

Primary Completion

May 25, 2025

Study Completion

May 26, 2025

Last Updated

June 4, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share

not in the policy of the department

Available IPD Datasets

Clinical Study Report (msabry776@yahoo.com)Access

Locations